A type-specific and neutralizing mouse MAb (V5) against human papillomavirus (HPV) type 16 capsids was found to block the serological reactivity of human sera with the corresponding capsids. Out of 352 human serum samples tested for the presence of IgG against HPV-16, more than 75 % of reactive sera were completely blocked by the V5 antibody.
Introduction
Infection with the major oncogenic types of human papillomavirus (HPV), notably HPV-16, is a major cause of cervical intraepithelial neoplasia (CIN), a precursor of cervical cancer (Schiffman et al., 1993) . The antibody response to intact HPV-16 capsids has over the past few years been validated as a type-restricted marker of past or present HPV infection (Andersson-Ellstro$ m et al., 1996 a ; Dillner et al., 1996 ; Kirnbauer et al., 1994 ; Wideroff et al., 1995 ; Wikstro$ m et al., 1995) . Serological testing has been most useful in assessing the spread and mode of transmission of HPV as well as for quantifying the HPV-associated excess risk for cancer (Chua et al., 1996 ; Lehtinen et al., 1996) .
Immunization of experimental animals with intact infectious PVs or with PV capsids regularly generates type-specific antibodies with high titres of virus neutralizing activity (Christensen et al., 1995) . Both the epitope(s) recognized by type-specific neutralizing MAbs (Christensen et al., 1996) and the epitope(s) recognized by the type-restricted human antibodies are dependent on the conformation of the capsid, i.e. the reactivity is lost by capsid disruption.
To study whether the epitope(s) recognized by human sera are related to the epitopes recognized by the neutralizing Author for correspondence : Joakim Dillner.
Fax j46 8 326702. e-mail joakim.dillner!mtc.ki.se Type-specific MAbs against HPV-6, -18 and -33 were also found to block serological reactivity with capsids of the corresponding HPV types for the majority of reactive human sera. The results suggest that most antibodies in human sera that are reactive with intact HPV capsids recognize the same or closely related major antigenic determinant(s).
MAbs, we investigated whether these MAbs were able to inhibit the reactivity of human sera with intact HPV capsids. A panel of MAbs against HPV capsids was tested for ability to block the reactivity of 352 human serum samples with HPV capsids. The majority of human sera were blocked, suggesting that the human serum antibody response against HPV capsids primarily recognizes the same or overlapping antigenic determinant(s).
Methods
Subjects and samples. A total of 352 human serum samples from 258 individuals was derived from three previous serological studies. Study 1 investigated HPV infection and incident squamous intraepithelial lesion (SIL) (Strickler et al., 1997) and consisted of 62 SIL patients of which 59 patients had HPV DNA (by hybrid capture) in their cervical samples (mean age 28 years). Thirty-one patients had the diagnosis low grade squamous intraepithelial lesion (LSIL) and 31 patients were diagnosed with a high grade squamous intraepithelial lesion (HSIL). Study 1 also comprised 44 control women with no cytological abnormality and no cervical HPV DNA (by PCR, mean age 29 years). Study 2 investigated sexual behaviour and the risk of HPV infection (Andersson-Ellstro$ m et al., 1996 a, b) and comprised 188 serum samples from 94 teenage girls (mean age 16n1 years) donated at enrolment and at a follow-up 2 years later. Forty-five samples were from virgins, whereas the other samples were from sexually experienced girls. None of the virgin girls had HPV DNA in the cervix (by PCR) or serum antibodies against HPV-16 or -33 (Andersson-Ellstro$ m et al., 1996 a, b) . In contrast, several virgin women had serum antibodies reactive with the HPV-6 capsid antigen preparation 0001-4778 # 1997 SGM CCAJ Z. Wang and others Z. Wang and others (unpublished observation). Study 3 analysed the presence of HPV DNA (by Southern blotting and PCR) and serum antibodies to HPV antigens among incident cervical cancer patients . A part of this study, consisting of 29 patients with cervical cancer (mean age 53 years) and 29 healthy blood donor controls (mean age 48 years) was used in the present study.
ELISA using MAbs. MAbs were raised against intact HPV L1 capsids as described (Christensen et al., 1996) . Type-specificity of the MAbs was verified in direct ELISAs using a variety of different HPV L1jL2 capsids (from HPV-6, -16, -18 and -33) prepared from recombinant baculoviruses. Intact HPV capsids were coated onto microtitre plates (Costar) in PBS at pH 7n2 ; denatured bovine papillomavirus (BPV) capsids coated after alkaline treatment were used as a control. The plates were blocked with 10 % horse serum in PBS (HS-PBS) at room temperature. In the experiments with 10 seropositive human serum samples, cell culture supernatants containing MAbs were added at two different dilutions, 1 : 10 (antibody excess) and half the dilution of the serial end-point dilution titre in HS-PBS. In experiments with all 352 sera, ascites fluids were added at a 1 : 1000 dilution (antibody excess). After 2 h incubation at room temperature, human serum samples were added at a 1 : 30 dilution in HS-PBS for a further 2 h reaction at room temperature. A monoclonal anti-human IgG-horseradish peroxidase conjugate (Eurodiagnostics) was added for 90 min at room temperature, followed by addition of substrate to detect the amount of human antibodies bound to the capsids. For the blocking experiments with MAbs V5 and L12, all sera were analysed twice. For the experiments with MAbs E12 and R5, all sera were analysed once. In addition, all sera with discrepant results and\or non-inhibited reactivity were retested two more times. The intra-assay coefficients of variation (CV) of the serological assay varied between 9n4 and 10n7 % in different assay runs and the inter-assay CV varied between 9n9 and 23n9%.
Inhibition ELISA using human sera or antipeptide hyperimmune sera. Intact HPV-16 L1jL2 capsids were coated onto ELISA plates as above. Following blocking with 10 % HS-PBS at room temperature, human serum samples or site-directed antipeptide hyperimmune sera were added at a 1 : 10 dilution in HS-PBS and incubated for 2 h at room temperature. MAb V5 was then added at a 1 : 2 000 000 dilution for a further 2 h incubation at room temperature. An anti-mouse IgG-horseradish peroxidase conjugate (Dako) was reacted for 90 min at room temperature, followed by substrate to detect the amount of MAb V5 bound to the capsids. These sets of experiments were reanalysed three or more times.
Measurement of the dissociation constant of MAb using ELISA. The method of Friguet et al. (1985) was followed. A serial dilution of HPV capsid concentrations (0n01-2n56 mg\ml) was mixed with MAbs at constant concentration and rotated for 20 h. The mixtures were transferred to ELISA plates (previously coated with HPV capsids) and incubated for 1 h at room temperature. An anti-mouse IgG-horseradish peroxidase conjugate was used to detect the amount of MAb that was bound to the capsids on the ELISA plates. That the equilibrium was not changed during ELISA plate incubation was verified by transfer of the supernatant to a second capsid-coated ELISA plate after incubation ; both the first and the second ELISA plate gave similar results. The dissociation constant (K d ) was then calculated by the formula (X\a l I ! kX\K d ), where X is the bound antibody concentration, a is the free antigen concentration and I ! is total antibody concentration. Affinity measurements were reanalysed three times. For each experiment, the affinity constant was estimated as the average of the affinity constants calculated using the data points on the linear part of the inhibition curve.
Results

ELISA reactivity of MAbs to HPV virus-like particles
To verify the type-specific reactivity with intact capsids containing both L1 and L2, MAbs L12, V5, R5 and E12 (raised against L1-containing capsids of respectively) were tested by ELISA with intact HPV L1-and L2-containing capsids of HPV-6, -16, -18 and -33. As expected, reactivity was HPV type-specific, with ELISA absorbances for the homologous HPV capsid ranging between 1n181 and 2n256 and absorbances for reactivity with capsids of the other HPV types ranging between 0n052 and 0n106.
Inhibition of reactivity of human sera with HPV-16 capsids by anti-HPV-16 MAbs
A set of eight MAbs (V5, E70, I23, U4, J4, C2, H5 and O7) against HPV-16 L1 capsids was used in excess for blocking the reactivity of 10 human sera selected at random from serum samples previously determined to be seropositive for HPV-16 capsids. One MAb (V5) could block the reactivity of all 10 human sera with HPV-16 capsids essentially to completion. One MAb (E70) decreased the reactivity of all the human sera, but did not achieve complete blocking. The other six MAbs (F18, I23, U4, J4, H5 and O7) did not inhibit some sera and showed partial inhibition of others (Fig. 1 a) . To investigate if the differences in blocking activity might have been due to differences in the antibody titres of the supernatants, a similar experiment was carried out where the supernatants were used for blocking at half the dilution of the twofold serial end-point dilution titre. The blocking reactivity pattern of the different MAbs was rather similar (Fig. 1 b) . To investigate if the strong blocking activity of V5 might be attributed to higher affinity of the MAb, the dissociation constants were measured. As shown in Table 2 , MAbs E70 and V5 were found to have the strongest affinity. In the reverse experiment, the 10 human serum samples were evaluated for their ability to block the reactivity of the V5 antibody with HPV capsids and all 10 sera conferred a strong inhibition, whereas five HPV-16 seronegative sera did not affect the binding (Fig. 1 c) .
Blocking experiments with site-directed hyperimmune sera
In an attempt to define the site recognized by the V5 antibody, the MAb was used for blocking the reactivity of 11 antipeptide hyperimmune sera previously found to be reactive with intact capsids by ELISA . The reactivities of the hyperimmune sera were only partially inhibited (Fig. 1 d) . We also evaluated the ability of the sitedirected antisera to block the reactivity of human serum samples with HPV-16 capsids. No single antiserum conferred any measurable blocking (data not shown). However, when a pool of all 11 site-directed antipeptide hyperimmune sera was CCBA Blocking of papillomavirus antibodies Blocking of papillomavirus antibodies used, the reactivities of 4 of 10 human serum samples were partially blocked (43n5-69n2 % reactivity was blocked).
Inhibition of human sera by the type-specific MAbs to HPV-6, -16, -18 and -33 capsids
The capacity of MAb V5 to block the reactivity of human sera was further evaluated using a panel of 352 human serum samples. In 76n4 % of cases, the reactivity with intact capsids was completely inhibited. The residual absorbances obtained in ELISA using intact capsids blocked with the V5 MAb were generally very close to the absorbance of the negative control (disrupted BPV capsids). Indeed, very similar results were obtained if the V5-blocked intact capsids were used as a negative control instead of the disrupted capsids [coefficient of determination (r#) l 0n915] (Fig. 2 a) . The reactivity of human sera with HPV-18 capsids was also strongly inhibited by the HPV-18-specific MAb R5 (Fig. 2 b) , whereas the reactivity of most sera with HPV-6 and -33 were only partially inhibited by the corresponding type-specific MAbs (Fig. 2 c, d ; Table 1 ).
Characteristics of non-inhibited serum samples
To investigate whether the reactivity in the few human serum samples that could not be blocked represented nonspecific reactivity, a comparison was made of the clinical characteristics of these subjects (Table 2) . However, most of these samples were from women with HPV-associated disease or at risk of HPV infection, rather than from controls.
Discussion
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whether the antibodies in human serum samples that react specifically with intact HPV capsids recognize the same or related epitopes. Our demonstration that MAbs V5, raised against HPV-16, and R5, raised against HPV-18, are capable of inhibiting the reactivity of a majority of reactive human sera suggests that the site that is recognized by these MAbs is also the immunodominant site recognized by most human sera following infection. The fact that the inhibition worked both ways, i.e. that the human sera also blocked V5, renders the possibility that inhibition may be due to allosteric effects unlikely, although it cannot be excluded. Since we did find a minority of sera whose reactivity with intact HPV-16 capsids was not affected by V5, we can conclude that, after blocking with V5, intact antigenically reactive capsids are maintained on the plates.
Our attempts to use site-directed antisera to define the primary amino acids reacting with V5 and with intact capsidreactive human sera were inconclusive. Although partial blocking was seen both in the experiment where V5 was used CCBD Z. Wang and others Z. Wang and others 
to block site-directed antisera and when site-directed antisera were used to block human sera, the partial blocking was observed for antisera against several different sites, suggesting that it may reflect mere steric hindrance when large parts of the capsid surface are covered with antibodies. In contrast, the blocking effect of V5 was much stronger than that of any other antibody. This may be partly explained by the higher affinity of V5 compared to that of most of the other MAbs. However, in spite of the fact that MAb E70 had higher affinity than V5, it inhibited human sera much more weakly, even when we adjusted for differences in antibody titre. Furthermore, whereas human sera are not able to distinguish between the evolutionarily divergent HPV-16 strains Zaire 1194 and 114K (Cheng et al., 1995) , the E70 antibody only recognized the 114K and not the Zaire strain of HPV-16. Similarly to the human sera, MAb V5 also recognizes both the Zaire and 114K strain of HPV-16 (Kirnbauer et al., 1994 ; Roden et al., 1997) .
Although the inhibitory effect of the type-specific MAbs against HPV-6 and -33 was much less than that of the MAbs against HPV-16 and -18, this should not be interpreted as implying that the reactivity in human sera against HPV-6 and -33 is more diverse than that against HPV-16 and -18. As demonstrated in the experiment where 11 different MAbs against HPV-16 were evaluated for their ability to block human sera, there were other HPV-16-specific MAbs (E70 and U4) that showed less complete inhibition than that seen with the V5 antibody. Thus, data from the present set of experiments cannot be used to determine whether the human antibody response against HPV-6 and -33 is more diverse or whether a MAb that does identify the major immunogenic site of the capsid of these HPVs has simply not yet been isolated.
The tendency of the reactivity against intact capsids that could not be blocked by type-specific MAbs to occur primarily in serum samples from patients with HPV-associated diseases is actually the expected finding from the point of view of immunodominance theory, since a broadening of the antibody response to react with multiple epitopes is expected to occur upon prolonged antigenic exposure. A related question is why only one out of 11 MAbs against HPV-16 capsids recognized the site that appears to be immunodominant for antibodies elicited in humans during natural infection. Possibly, this may be explained by the fact that immunization of mice for isolation of MAbs uses multiple immunizations with excess amounts of antigen compared with the amounts released during natural infection.
If most human sera are directed against the same site as MAb V5, this would suggest that most of the human antibodies that react with intact HPV-16 capsids should have HPV-16 neutralizing capacity, since of the MAbs against HPV-16, V5 has the strongest neutralizing capacity (Roden et al., 1997) . Previous studies using HPV-11 have indeed indicated that most human sera that were specifically reactive with intact HPV-11 capsids did possess neutralizing activity (Christensen et al., 1992) . It would be interesting to determine whether HPV-16-neutralizing ability differs between the human serum antibodies against intact HPV-16 capsids that are or are not blocked by V5 and whether occurrence of non-neutralizing antibodies is of pathogenic significance in the development of HPV-associated diseases.
Papillomavirus capsids have been very successful for prophylactic vaccination in several animal model systems (Breitburd et al., 1995 ; Schiller & Roden, 1995) and there are several initiatives to develop papillomavirus-capsid-based vaccines for human use (Schiller & Okun, 1996) . Since there are several different technologies possible for capsid production, purification and stabilization, there is a strong need for characterization of the epitope exposure of various HPV vaccine preparations. To enable this application to be realized, it must be determined whether the epitopes recognized by specific MAbs are immunodominant or functionally important epitopes. The present study suggests that exposure of V5-and R5-defined epitopes is a desirable property of vaccine candidates against HPV-16 and -18.
